Skip to main
PLRX

PLRX Stock Forecast & Price Target

PLRX Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Pliant Therapeutics is given a HOLD rating by the financial analyst due to the lack of strong clinical data for their lead product candidate PLN-101095. The updated cash position and share counts have led to a decrease in the 12-month price target from $4 to $3 per share. Despite this, the company has a strong cash position of $192.4M that is expected to fund operations well into the second half of 2028.

Bears say

Pliant Therapeutics is experiencing strong preliminary results for their product PLN-101095, showing favorable response rates in a heavily pretreated patient population and inducing large increases in IFN-γ. However, the company's Ph1b trial design based on key findings from their Ph1 may lead to limited indication expansion. Additionally, there is a lack of data on the safety and efficacy in a larger patient population.

PLRX has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pliant Therapeutics (PLRX) Forecast

Analysts have given PLRX a Hold based on their latest research and market trends.

According to 3 analysts, PLRX has a Hold consensus rating as of Jul 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pliant Therapeutics (PLRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.